期刊
CLINICAL CANCER RESEARCH
卷 28, 期 15, 页码 3182-3184出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-22-0541
关键词
-
类别
资金
- Department of Pathology of New York University Grossman School of Medicine (New York, NY)
4-1BB has long been considered a promising target for cancer immunotherapy, but early targeted agents showed significant liver toxicity. A new approach is being developed to circumvent hepatotoxicity by directing 4-1BB agonism to the tumor microenvironment using a bispecific molecule targeting the tumor-associated immune checkpoint molecule PD-L1.
4-1BB has been considered a promising target in cancer immunotherapy for decades. Nevertheless, early 4-1BB-targeted agents demonstrated significant liver immuno-toxicity. A new wave of 4-1BB-based therapy is being developed to circumvent hepatotoxicity with a bispecific molecule that directs 4-1BB agonism to the tumor microenvironment by targeting tumor-associated immune checkpoint molecule PD-L1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据